β2激动剂在运动中的流行及其对运动成绩的影响

A. A. Derevoedov, A. Zholinsky, V. Feshchenko, I. Vykhodets, A. Pavlova
{"title":"β2激动剂在运动中的流行及其对运动成绩的影响","authors":"A. A. Derevoedov, A. Zholinsky, V. Feshchenko, I. Vykhodets, A. Pavlova","doi":"10.47529/2223-2524.2021.3.6","DOIUrl":null,"url":null,"abstract":"Respiratory disorders caused by exercise are expressed in the development of exercise-induced bronchoconstriction (EIB) and exercise-induced asthma (EIA), which are observed in athletes, especially in cyclic sports, much more often than in the population. Ventilation impairments are exacerbated by inhaled allergens, industrial pollutants and adverse environmental conditions, which increase the risk of EIB and asthma symptoms in athletes. The use of β2-agonists can prevent or eliminate ventilation disorders, however, it requires taking into account current anti-doping rules, which allow the use of certain substances in sports without a request for therapeutic use. The studies of the influence of β2-agonists on functional indicators of athletes and sports performance do not allow to make an unambiguous conclusion about its results. Medications with β2-agonists, approved for use in sports in the form of inhalation, do not have a significant effect on the performance of athletes at major sports competitions. At the same time, the systemic use of these substances and the use of any form of terbutaline caused a positive dynamics in functional indicators, which could lead to an illegal increase in the effectiveness of sports performance. Most of the conclusions about the effect of β2-agonists on outcome are based on a small number of studies, their heterogeneity, and an insignificant number of observations. It is necessary to continue studying the effects of β2-agonists in the course of randomized clinical trials in order to individualize therapy and prevent bronchial obstruction in athletes","PeriodicalId":309619,"journal":{"name":"Sports medicine: research and practice","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"β2-agonists in sports: prevalence and impact on athletic performance\",\"authors\":\"A. A. Derevoedov, A. Zholinsky, V. Feshchenko, I. Vykhodets, A. Pavlova\",\"doi\":\"10.47529/2223-2524.2021.3.6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Respiratory disorders caused by exercise are expressed in the development of exercise-induced bronchoconstriction (EIB) and exercise-induced asthma (EIA), which are observed in athletes, especially in cyclic sports, much more often than in the population. Ventilation impairments are exacerbated by inhaled allergens, industrial pollutants and adverse environmental conditions, which increase the risk of EIB and asthma symptoms in athletes. The use of β2-agonists can prevent or eliminate ventilation disorders, however, it requires taking into account current anti-doping rules, which allow the use of certain substances in sports without a request for therapeutic use. The studies of the influence of β2-agonists on functional indicators of athletes and sports performance do not allow to make an unambiguous conclusion about its results. Medications with β2-agonists, approved for use in sports in the form of inhalation, do not have a significant effect on the performance of athletes at major sports competitions. At the same time, the systemic use of these substances and the use of any form of terbutaline caused a positive dynamics in functional indicators, which could lead to an illegal increase in the effectiveness of sports performance. Most of the conclusions about the effect of β2-agonists on outcome are based on a small number of studies, their heterogeneity, and an insignificant number of observations. It is necessary to continue studying the effects of β2-agonists in the course of randomized clinical trials in order to individualize therapy and prevent bronchial obstruction in athletes\",\"PeriodicalId\":309619,\"journal\":{\"name\":\"Sports medicine: research and practice\",\"volume\":\"39 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sports medicine: research and practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47529/2223-2524.2021.3.6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sports medicine: research and practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47529/2223-2524.2021.3.6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

运动引起的呼吸系统疾病表现为运动性支气管收缩(EIB)和运动性哮喘(EIA)的发展,这在运动员中,特别是在循环运动中,比在人群中更常见。吸入的过敏原、工业污染物和不利的环境条件加剧了通气障碍,增加了运动员发生EIB和哮喘症状的风险。β2激动剂的使用可以预防或消除通气障碍,然而,这需要考虑到当前的反兴奋剂规则,该规则允许在没有治疗用途的情况下在运动中使用某些物质。关于β2激动剂对运动员功能指标和运动成绩影响的研究并不能对其结果做出明确的结论。含有β2激动剂的药物,被批准以吸入形式用于运动,对运动员在重大体育比赛中的表现没有显著影响。同时,系统使用这些物质和使用任何形式的特布他林在功能指标上造成积极的动态,这可能导致非法提高运动成绩的有效性。大多数关于β2激动剂对预后影响的结论是基于少数研究,它们的异质性和数量微不足道的观察结果。有必要在随机临床试验过程中继续研究β2激动剂的作用,以便个体化治疗和预防运动员支气管阻塞
本文章由计算机程序翻译,如有差异,请以英文原文为准。
β2-agonists in sports: prevalence and impact on athletic performance
Respiratory disorders caused by exercise are expressed in the development of exercise-induced bronchoconstriction (EIB) and exercise-induced asthma (EIA), which are observed in athletes, especially in cyclic sports, much more often than in the population. Ventilation impairments are exacerbated by inhaled allergens, industrial pollutants and adverse environmental conditions, which increase the risk of EIB and asthma symptoms in athletes. The use of β2-agonists can prevent or eliminate ventilation disorders, however, it requires taking into account current anti-doping rules, which allow the use of certain substances in sports without a request for therapeutic use. The studies of the influence of β2-agonists on functional indicators of athletes and sports performance do not allow to make an unambiguous conclusion about its results. Medications with β2-agonists, approved for use in sports in the form of inhalation, do not have a significant effect on the performance of athletes at major sports competitions. At the same time, the systemic use of these substances and the use of any form of terbutaline caused a positive dynamics in functional indicators, which could lead to an illegal increase in the effectiveness of sports performance. Most of the conclusions about the effect of β2-agonists on outcome are based on a small number of studies, their heterogeneity, and an insignificant number of observations. It is necessary to continue studying the effects of β2-agonists in the course of randomized clinical trials in order to individualize therapy and prevent bronchial obstruction in athletes
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信